Last updated: April 16, 2024
Sponsor: Sanguine Biosciences
Overall Status: Terminated
Phase
N/A
Condition
Sarcoidosis
Treatment
Specimen Donation
Clinical Study ID
NCT05915897
SAN-09687
Ages 18-85 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- The participant is willing and able to provide written informed consent
- The participant is willing and able to provide appropriate photo identification
- Participants aged 18 to 85
- Participants have been diagnosed with Chronic Granulomatous Disease (CGD)
- Subjects who have a confirmed p47phox CGD mutation or Subjects who have a confirmedX-linked CGD mutation
Exclusion
Exclusion Criteria:
- Participants who are pregnant or are nursing
- Participants with a known history of HIV, hepatitis, or other infectious diseases
- Participants who have taken an investigational product in the last 30 days
- Participants who have experienced excess blood loss, including blood donation, definedas 250 mL in the last month or 500 mL in the previous two months
Study Design
Total Participants: 6
Treatment Group(s): 1
Primary Treatment: Specimen Donation
Phase:
Study Start date:
May 23, 2023
Estimated Completion Date:
March 25, 2024
Connect with a study center
Sanguine BioSciences, Inc.
Woburn, Massachusetts 01801
United StatesSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.